Literature DB >> 12931860

Archazolids, new cytotoxic macrolactones from Archangium gephyra (Myxobacteria). Production, isolation, physico-chemical and biological properties.

Florenz Sasse1, Heinrich Steinmetz, Gerhard Höfle, Hans Reichenbach.   

Abstract

Novel cytotoxic compounds, archazolid A and B, were isolated from the culture broth of strains of the myxobacteria Archangium gephyra and Cystobacter sp. Archazolids consist of a macrocyclic lactone ring with a thiazole side chain and showed high activity against mammalian cells. The IC50 values with different cell lines ranged from 0.1 to 1 ng/ml. An incubation of PtK2 potoroo cells with archazolid A (5 ng/ml) led to the formation of vacuoles in the ER, a phenomenon that is typical for inhibitors of V-ATPases, like concanamycin and bafilomycin. We therefore assume that archazolid is an inhibitor of the V-ATPase of higher cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12931860     DOI: 10.7164/antibiotics.56.520

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  22 in total

1.  Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B.

Authors:  Rebecca Hamm; Yoshikazu Sugimoto; Heinrich Steinmetz; Thomas Efferth
Journal:  Invest New Drugs       Date:  2014-07-29       Impact factor: 3.850

2.  The binding site of the V-ATPase inhibitor apicularen is in the vicinity of those for bafilomycin and archazolid.

Authors:  Christin Osteresch; Tobias Bender; Stephanie Grond; Paultheo von Zezschwitz; Brigitte Kunze; Rolf Jansen; Markus Huss; Helmut Wieczorek
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

Review 3.  Life in cellulose houses: symbiotic bacterial biosynthesis of ascidian drugs and drug leads.

Authors:  Eric W Schmidt; Mohamed S Donia
Journal:  Curr Opin Biotechnol       Date:  2010-11-01       Impact factor: 9.740

4.  Screening of small molecules affecting mammalian P-body assembly uncovers links with diverse intracellular processes and organelle physiology.

Authors:  Javier P Martínez; Gemma Pérez-Vilaró; Yazh Muthukumar; Nicoletta Scheller; Tatjana Hirsch; Randi Diestel; Heinrich Steinmetz; Rolf Jansen; Ronald Frank; Florenz Sasse; Andreas Meyerhans; Juana Díez
Journal:  RNA Biol       Date:  2013-11       Impact factor: 4.652

5.  V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.

Authors:  Karin von Schwarzenberg; Tamás Lajtos; Làszló Simon; Rolf Müller; György Vereb; Angelika M Vollmar
Journal:  Mol Oncol       Date:  2013-09-05       Impact factor: 6.603

6.  MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.

Authors:  Lina S Schneider; Melanie Ulrich; Thorsten Lehr; Dirk Menche; Rolf Müller; Karin von Schwarzenberg
Journal:  Mol Oncol       Date:  2016-04-27       Impact factor: 6.603

7.  Archazolid A binds to the equatorial region of the c-ring of the vacuolar H+-ATPase.

Authors:  Svenja Bockelmann; Dirk Menche; Sven Rudolph; Tobias Bender; Stephanie Grond; Paultheo von Zezschwitz; Stephen P Muench; Helmut Wieczorek; Markus Huss
Journal:  J Biol Chem       Date:  2010-09-30       Impact factor: 5.157

8.  Synthesis of a C1-C23 fragment of the archazolids and evidence for V-ATPase but not COX inhibitory activity.

Authors:  Gregory W O'Neil; Alexander M Craig; John R Williams; Jeffrey C Young; P Clint Spiegel
Journal:  Synlett       Date:  2017-02-08       Impact factor: 2.454

9.  In vitro efficacy of Myxococcus fulvus ANSM068 to biotransform aflatoxin B₁.

Authors:  Shu Guan; Lihong Zhao; Qiugang Ma; Ting Zhou; Ning Wang; Xinxu Hu; Cheng Ji
Journal:  Int J Mol Sci       Date:  2010-10-20       Impact factor: 5.923

10.  Synthesis of the C1-C17 fragment of the archazolids by complex cis-homodimer cross metathesis.

Authors:  Steven M Swick; Sara L Schaefer; Gregory W O'Neil
Journal:  Tetrahedron Lett       Date:  2015-06-24       Impact factor: 2.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.